Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
 
Sign in
Join now
Published in COVID-19 and
1 other channel

Journal Scan / Research · October 14, 2022

Efficacy and Safety of a Single Dose of Casirivimab and Imdevimab for the Prevention of COVID-19 Over an 8-Month Period

The Lancet Infectious Diseases

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Emmett Kistler MD

The Lancet Infectious Diseases
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
Lancet Infect Dis 2022 Oct 01;22(10)1444-1454, GA Herman, MP O'Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, KJ Bar, RV Barnabas, DH Barouch, MS Cohen, CB Hurt, DR Burwen, MA Marovich, BJ Musser, JD Davis, KC Turner, A Mahmood, AT Hooper, JD Hamilton, J Parrino, D Subramaniam, A Baum, CA Kyratsous, AT DiCioccio, N Stahl, N Braunstein, GD Yancopoulos, DM Weinreich

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated